Israeli company Virility Medical for premature ejaculation is raising $ 8 million in a funding round led by Arkin Investments, which is investing $ 6 million, and with the participation of Almeda Ventures Limited Partnership (TASE: AMDA), which invests $ 1.5 million, and other investors, announced the R&D partnership. Related articles Combined premature ejaculation treatment Virility raises NIS 3m Virility Medical is in the advanced clinical stage to develop a disposable skin patch with neuromodulating potential, which stimulates nerves and adjacent muscles to delay ejaculation. The company was founded at the NGT3 Technology Incubator in Nazareth by CTO Tal Gollan and is currently managed by CEO David Salton. Virility will use the current funding round to obtain marketing approval from the U.S. Food and Drug Administration (FDA). Almeda Ventures held its initial public offering on the TASE exchange in October 2020, and since then its share price has increased by 4.7%, bringing the market value to 63 million shekels. Almeda Ventures’ partners are Tzachi Sultan, Chairman of Discount Capital Underwriting, Dr. Eret Yaniv and Amir Platt, both former Accelmed partners. To date, Almeda’s portfolio contains BioProtect to protect healthy tissues during prostate cancer treatment, digital health company TailorMed, tissue engineering company Nurami Medical (also a graduate of NGT3), and Lumen – Metaflow to track metabolism. Posted by Globes, Israel business news – en.globes.co.il – February 8, 2021 © Copyright Globes Publisher Itonut (1983) Ltd. 2021
Common premature ejaculation correction raised $ 8 million
0 Comments